Global Blood Therapeutics Inc (NASDAQ:GBT)

54.68
Delayed Data
As of Sep 20
 +0.86 / +1.60%
Today’s Change
30.15
Today|||52-Week Range
64.94
+33.20%
Year-to-Date
FDA Grants Priority Review to Global Blood's SCD Candidate
Sep 06 / Zacks.com - Paid Partner Content
Why Global Blood Therapeutics Stock Jumped 10.9% Today
Sep 05 / MotleyFool.com - Paid Partner Content
Why Is Global Blood (GBT) Up 6.2% Since Last Earnings Report?
Sep 06 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close53.82
Today’s open54.30
Day’s range53.58 - 54.86
Volume1,282,029
Average volume (3 months)910,635
Market cap$3.2B
Data as of 4:00pm ET, 09/20/2019

Growth & Valuation

Earnings growth (last year)-23.39%
Earnings growth (this year)-19.35%
Earnings growth (next 5 years)+0.30%
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book5.25

Competitors

 Today’s
change
Today’s
% change
ALKSAlkermes Plc-0.02-0.09%
TAROTaro Pharmaceutical ...+0.81+1.01%
MRTXMirati Therapeutics ...+1.44+1.57%
RETAReata Pharmaceutical...+2.57+2.80%
Data as of 6:30pm ET, 09/20/2019

Financials

Next reporting dateNovember 6, 2019
EPS forecast (this quarter)-$1.05
Annual revenue (last year)$0.00
Annual profit (last year)-$174.2M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Ted W. Love
Senior Vice President-
Operations
Peter Radovich
Corporate headquarters
South San Francisco, California

Forecasts